The University of Arizona/Arizona Cancer Center (ACC) has been a continuously funded member institution of the Southwest Oncology Group (SWOG) since 1974. The current renewal application requests funding for years 37-41 to continue and expand institutional participation in the clincal research and treatment goals of SWOG via SWOG-and SWOG-endorsed efforts.
Specific aims and objectives remain as follows: 1. To continue to meet institutional scientific leadership and core service commitments within the Group, including: (a) protocol coordination (multiple studies);(b) disease and discipline committee administration;(c) reference and repository laboratory administration (including lymphoma, myeloma);(d) Group quality assurance and quality control. 2. To continue to promote the rapid integration of promising new research leads, including those developed at the ACC, into cooperative group testing to provide treatment options for a larger population of patients and improved patient care. 3. To continue to meet institutional clinical research commitments in the recruitment of appropriate patients for SWOG and SWOG-endorsed studies and all attendant commitments to longterm fllowup, quality assurance, quality control. 4. To continue and increase effforts to promote physician and patient awareness of and participation in SWOG and SWOG-endorsed clinical trials and outreach programs. 5. To continue efforts to understand factors affecting accrual paticularly those in special populations (eg, minority, elderly, financially disadvantaged) and to implement appropriate interventions where possible.

Public Health Relevance

The ACC has a long history of scientific and administrative leadership in the SWOG and participation in national cooperative group treatment and prevention studies. A key element of its scientific contribution is institutional clinical and laboratory pilot work leading to national testing to establish new standards of care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA013612-37
Application #
7766876
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-01-01
Project End
2012-12-31
Budget Start
2010-07-01
Budget End
2010-12-31
Support Year
37
Fiscal Year
2010
Total Cost
$310,552
Indirect Cost
Name
University of Arizona
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Goss, Paul E; Ingle, James N; Pritchard, Kathleen I et al. (2016) Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 375:209-19
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Barr, Paul M; Li, Hongli; Spier, Catherine et al. (2015) Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol 33:2399-404
Kelly, Jennifer L; Salles, Gilles; Goldman, Bryan et al. (2015) Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. J Clin Oncol 33:1482-90
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8

Showing the most recent 10 out of 207 publications